Inke, S.A.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
2
Ending by 2030
Sep 2028
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Oct 12, 2027The maintenance fee for Polymorphic form of a long-acting beta-2 adrenoceptor agonist (US 9,309,186) comes due Oct 12, 2027. Unpaid by Apr 12, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,129,522 | Method for preparing a mixed solvate of olanzapine In force · From the USPTO record | In force | From the USPTO record | |
| US 8,304,426 | Polymorphic form of Granisetron base, methods for obtaining it and formulation containing it In force · From the USPTO record | In force | From the USPTO record | |
| US 8,455,655 | Preparation of dihydropyridines In force · From the USPTO record | In force | From the USPTO record | |
| US 8,927,743 | Process for Obtaining Dronedarone In force · High confidence | In force | High confidence | |
| US 9,505,771 | Stable micronised monoclin form of asenapine maleate and its synthesis In force · From the USPTO record | In force | From the USPTO record | |
| US 9,533,994 | Monoclinic crystalline form of asenapine maleate with a specific particle size distribution In force · From the USPTO record | In force | From the USPTO record | |
| US 9,309,186 | Polymorphic form of a long-acting beta-2 adrenoceptor agonist In force · From the USPTO record | In force | From the USPTO record | |
| US 10,131,630 | Process for preparing (3RS)-3-[(2SR)-(2-cyclopentyl-2-hydroxy-2-phenylacetyl)oxy]-1,1-dimethylpyrrolidinium bromide In force · From the USPTO record | In force | From the USPTO record | |
| US 10,888,500 | Particle size stabilization process In force · From the USPTO record | In force | From the USPTO record | |
| US 10,800,748 | Process for the manufacture of R-6-hydroxy-8-[1-hydroxy-2-[2-(4-methoxyphenyl)-1,1-dimethylethylaminoethyl]-2H-1,4-benzoxazin-3(4H)-one hydrochloride In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 11: 12 lapsed for an unpaid fee · 6 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 pending · 2 no status recorded